Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College
of
Medicine
(COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Schultz, Teri
Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
- College: College
of
Medicine
(COM)
- Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
- Licensing Officer: Schultz, Teri
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College
of
Medicine
(COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Schultz, Teri
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness
of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College
of
Medicine
(COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need
Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
- College: College
of
Medicine
(COM)
- Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
- Licensing Officer: Schultz, Teri
Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance
of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings.
The Need
The rise of these resilient multi-drug resistant bacteria has …
- College: College
of
Medicine
(COM)
- Inventors: Pancholi, Vijay
- Licensing Officer: Schultz, Teri
Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs
of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart.
The Need
In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
- College: College
of
Medicine
(COM)
- Inventors: Lewandowski, E. Douglas; Carley, Andrew
- Licensing Officer: Schultz, Teri
A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
- College: College
of
Medicine
(COM)
- Inventors: Tedeschi, Andrea
- Licensing Officer: Schultz, Teri
Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need
Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
- College: College
of
Medicine
(COM)
- Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
- Licensing Officer: Bhatti, Hamid
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College
of
Medicine
(COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
- College: College
of
Medicine
(COM)
- Inventors: Chu, Nam; Le, Nhat
- Licensing Officer: Taysavang, Panya
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College
of
Medicine
(COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%.
The Need
Despite extensive efforts, there has been no s…
- College: College
of
Medicine
(COM)
- Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
- Licensing Officer: Schultz, Teri
Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives
of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
- College: College
of
Medicine
(COM)
- Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
- Licensing Officer: Schultz, Teri
Modulation of Mismatch Repair and Genomic Stability by miR-155
TS-062322 — The Need
The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo; Valeri, Nicola
- Licensing Officer: Willson, Christopher
Diagnosis of Chemoresistant Ovarian Cancer.
TS-062306 — The Need
Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo; Vecchione, Andrea
- Licensing Officer: Willson, Christopher
Microrna-21, Mismatch Repair, and Colorectal Cancer
TS-062305 — The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or a…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo; Valeri, Nicola
- Licensing Officer: Willson, Christopher
Advancing Cancer-Related Technology for Better Prognosis and Treatment
TS-062303 — The Need:
Cancer continues to be a significant global health challenge, with conditions like non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) often diagnosed at advanced stages, resulting in poor prognoses. Existing treatment methods, such as TRAIL-based therapy, face obstacle…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo
- Licensing Officer: Willson, Christopher
MicroRNA signatures in human ovarian cancer
TS-062298 — The Need:
Ovarian cancer remains a significant challenge in the field of
medicine, with late-stage diagnosis and limited effective treatments contributing to high mortality rates. The need for improved diagnostic tools and targeted therapies is evident to address this aggressive disease. Convention…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo
- Licensing Officer: Willson, Christopher
Composition and Methods for Lung Cancer Diagnosis and Treatment
TS-062296 — The Need: Advancing Lung Cancer Detection and Treatment
Lung cancer continues to be a global health concern, accounting for the highest number of cancer-related deaths worldwide. In the United States, it is the leading cause of cancer mortality for both men and women, with a disheartening five-year…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo; Calin, George
- Licensing Officer: Willson, Christopher
Composition and Methods for Breast Cancer Diagnosis and Treatment
TS-062295 — The Need:
Breast cancer continues to be a significant health challenge, affecting a large number of women worldwide and remaining the second leading cause of cancer-related deaths among women in the United States. Despite advancements in detection and treatment, there is no universally successful m…
- College: College
of
Medicine
(COM)
- Inventors: Croce, Carlo; Calin, George
- Licensing Officer: Willson, Christopher
A novel VSV-based vaccine platform for Zika virus
TS-062261 — The Need: Addressing the Zika Virus Outbreak
The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…
- College: College
of
Medicine
(COM)
- Inventors: Peeples, Mark; Li, Jianrong
- Licensing Officer: Dahlman, Jason "Jay"
Peptide-based therapeutic intervention for Cardiac Ryanopathies
TS-062097 — Novel polypeptides and polynucleotides targeting RyR2 to address dysregulated Ca2+ release.
The cardiac ryanodine receptor channel 2 (RyR2) is known as the Ca2+ release channel of the sarcoplasmic reticulum (SR), and is believed to be a good therapeutic target in a group of certain heart diseases, known as cardiac ryanopathies. A number of mutations in the RyR2 gene have been linked to a w…
- College: College
of
Medicine
(COM)
- Inventors: Singh, Harpreet
- Licensing Officer: Schultz, Teri
Treating Obesity and Cardiovascular Disease Via Genetic Manipulation of Skin Tissue
TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all adults in the US. CVD encompasses a number of conditions that affect the heart and vasculature. CVD can arise in response to multiple factors, including obesity. Obesity elevates the…
- College: College
of
Medicine
(COM)
- Inventors: Stanford, Kristin; Gallego Perez, Daniel; Ziolo, Mark
- Licensing Officer: Schultz, Teri
FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics
of salmonellosis, as well as small molecule inhibitors
of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy
of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
- College: College
of
Medicine
(COM)
- Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
- Licensing Officer: Schultz, Teri
Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 —
A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center
of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
- College: College
of
Medicine
(COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 —
A novel protein-drug conjugate
of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
- College: College
of
Medicine
(COM)
- Inventors: Williams, Terence; Lee, Robert
- Licensing Officer: He, Panqing
Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 —
CRISPR/Cas 9 mediated targeting
of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription
of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development
of aGVHD in patients.
The Need
More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
- College: College
of
Medicine
(COM)
- Inventors: Ranganathan, Parvathi; Garzon, Ramiro
- Licensing Officer: He, Panqing
Show More Technologies